gms | German Medical Science

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2017)

24.10. - 27.10.2017, Berlin

Silver-coated endoprosthetic replacement of the proximal humerus in case of tumour – is there an increased risk of periprosthetic infection by using a trevira tube?

Meeting Abstract

  • presenting/speaker Jan Schmolders - Universitätsklinikum Bonn, Orthopädie/Unfallchirurgie, Bonn, Germany
  • Sebastian Koob - Universitätsklinikum Bonn, Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Bonn, Germany
  • Michael Kehrer - Orthopädie und Unfallchirurgie Uniklinik Bonn, Universitätsklinik Bonn, Orthopädie und Unfallchirurgie, Bonn, Germany
  • Dieter C. Wirtz - Universitätsklinikum Bonn, Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Bonn, Germany
  • Peter Pennekamp - Universitätsklinikum Bonn, Klinik für Orthopädie und Unfallchirurgie, Bonn, Germany
  • Andreas C. Strauß - Universitätsklinikum Bonn, Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Bonn, Germany

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2017). Berlin, 24.-27.10.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocIN35-14

doi: 10.3205/17dkou092, urn:nbn:de:0183-17dkou0927

Veröffentlicht: 23. Oktober 2017

© 2017 Schmolders et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objectives: The aim of our study was to evaluate if there is an increased risk of periprosthetic infection (PJI) in patients following replacement of the proximal humerus by using a modular tumor prosthesis in combination with a trevira tube.

Methods: Thirty patients were treated by using a modular tumor endoprosthesis (MUTARS®) following intraarticular resection of the proximal humerus. Fifteen patients received treatment by using a trevira tube. In fifteen further cases the use of a trevira tube was not necessary. The mean follow-up time was 26 months (range: 24 months to 84 months). Both, Enneking Score and Range of Motion (ROM), was evaluated. Further radiographs were obtained in two planes.

Results and Conclusion: The survival rate one year after surgery was 83% and 63% after two years. We recorded a 96% survival of the limb two years after surgery. We also observed only one case of periprosthetic joint infection (PJI) in the entire follow-up period in one patient who received treatment with a trevira tube. The mean Enneking score was 20 points (range 8 to 26 points). ROM was equal in both study groups. In total 20% of the treated patients (n=6) suffered complications.

Replacement of the proximal humerus by using a trevira tube in combination with a modular tumor endoprosthesis is a safe and viable treatment option for both, bone tumors and metastases. There is no statistically significant increased risk of infection by using trevira tube even among immunosuppressed patients.